AXL vs HEPS

The company exhibits weak fundamental health with a Piotroski F-Score of 4/9, indicating borderline stability, and lacks an Altman Z-Score to confirm financial distress risk. Despite a recent strong price run-up (+44.8% 1Y), profitability is thin, growth is negative, and leverage is extremely high (Debt/Equity: 3.81). Valuation metrics are mixed, with a low P/S of 0.17 suggesting potential undervaluation, but elevated P/E of 23.66 and negative earnings growth raise concerns. Analysts concur with a 'hold' rating, aligning with the uncertain outlook.

The company exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9, indicating fundamental weakness across almost all health metrics. While revenue growth remains strong at 36.9% YoY, this has failed to translate into profitability, as evidenced by a catastrophic ROE of -213.73% and a consistent track record of missing earnings estimates. Liquidity is a primary concern with a Quick Ratio of 0.59 and a Current Ratio below 1.0, suggesting an inability to meet short-term obligations. Despite a positive analyst target price, the deterministic data points to a high-risk profile with significant insolvency concerns.